Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06196671 | Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer(PTCA199-8) | not yet recruiting | Phase 2 | 30 | Fudan UniversityOTHER | 0 | Aug 7, 2025 | clinicaltrials |
| NCT07095621 | Feasibility and Effectiveness of Three-day Discharge After Distal Pancreatectomy(3DD) | not yet recruiting | — | 35 | IRCCS San RaffaeleOTHER | 0 | Aug 7, 2025 |
| clinicaltrials |
| NCT07108504 | Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2025 | clinicaltrials |
| NCT07097064 | Evaluation of the Stereotactic MR-guided Adaptive Radiotherapy for Locally Advanced Pancreatic Cancers(RAIPANC) | not yet recruiting | Phase 2 | 160 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT07093593 | Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs(RAMA) | not yet recruiting | N/A | 260 | Centre Georges Francois LeclercOTHER | 0 | Jul 30, 2025 | clinicaltrials |
| NCT07087392 | Inverted-Ω Anastomosis in Laparoscopic Duodenum-Preserving Pancreatic Head Resection or Laparoscopic Central Pancreatectomy | not yet recruiting | N/A | 20 | West China HospitalOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT06541561 | Efficacy of TEAS on Postoperative Pain and Recovery in Patients Undergoing Pancreatectomy | not yet recruiting | N/A | 132 | West China HospitalOTHER | 0 | Jul 17, 2025 | clinicaltrials |
| NCT07064447 | Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator | not yet recruiting | — | 260 | Germans Trias i Pujol HospitalOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07055568 | A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer | not yet recruiting | N/A | 18 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jul 9, 2025 | clinicaltrials |
| NCT07056972 | Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms(TRIVIAL) | not yet recruiting | — | 394 | Azienda Ospedaliera di PadovaOTHER | 0 | Jul 9, 2025 | clinicaltrials |
| NCT07012694 | 22G-Adapt vs 22G-Franseen Needle Biopsy in EUS-Guided Tissue Acquisition of Solid Lesions | not yet recruiting | N/A | 576 | Huazhong University of Science and TechnologyOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT04901741 | Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer(OPTIMUS) | not yet recruiting | Phase 2 | 60 | TME Pharma AGINDUSTRY | 0 | Jun 27, 2025 | clinicaltrials |
| NCT07026123 | A Real-world Study of Liposomal Irinotecan (Onivyde)-Based Therapy in Patients With Locally Advanced/Metastatic Pancreatic Cancer in China | not yet recruiting | — | 40 | RenJi HospitalOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07014709 | Impact of GLP-1 Receptor Agonists on Patients With IPMN(IPMN-GLP1RA) | not yet recruiting | — | 30 | Hôpital FribourgeoisOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014254 | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies | not yet recruiting | N/A | 20 | Xijing HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06999512 | Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer(HPB70+) | not yet recruiting | Phase 2 / Phase 3 | 526 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06991491 | Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004) | not yet recruiting | Phase 2 | 29 | West China HospitalOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT06960122 | Clinical Study on Fecal Microbiota Transplantation for Diarrhea After Total Pancreatectomy(FMT-TP) | not yet recruiting | N/A | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06954753 | Predicting Cancer in Pancreatic Cystic Lesions Through Artificial Intelligence | not yet recruiting | — | 250 | Centre Hospitalier Universitaire de NiceOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT06162468 | Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts | not yet recruiting | N/A | 20 | University of Auckland, New ZealandOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06938503 | AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 48 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Apr 22, 2025 | clinicaltrials |
| NCT06913218 | A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC | not yet recruiting | Phase 1 | 60 | AkesoINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911021 | 68Ga-FAPI-46 in Staging of Pancreatic Adenocarcinoma | not yet recruiting | N/A | 20 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06779318 | Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis | not yet recruiting | Phase 4 | 464 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06743386 | Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )(RadioFAP) | not yet recruiting | N/A | 30 | French Society of Digestive EndoscopyOTHER | 0 | Mar 11, 2025 | clinicaltrials |
| NCT06868693 | Neoadjuvant Chemotherapy for Elderly with Pancreatic Head Cancer(PEACE) | not yet recruiting | — | 240 | Azienda Unita Sanitaria Locale di PiacenzaOTHER | 0 | Mar 11, 2025 | clinicaltrials |
| NCT06866977 | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chemotherapy for Advanced Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 10 | Xiangya Hospital of Central South UniversityOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT06844773 | Chemoradiotherapy in Elderly Patients with Locally Advanced Pancreatic Cancer (70+). | not yet recruiting | — | 36 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06750861 | QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06807112 | The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Ductal Adenocarcinoma: The Role of Biomarkers in Determining the Prognosis of Pancreatic Ductal Adenocarcinoma | not yet recruiting | — | 39 | Charles University, Czech RepublicOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05562297 | Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer | not yet recruiting | Phase 2 | 50 | Shanghai Zhongshan HospitalOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06787807 | Proteomic Analysis of Patients Undergoing Bariatric Surgery | not yet recruiting | N/A | 103 | Universidade Federal de PernambucoOTHER | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06760741 | PREVENPANC Project: a Spanish Multicenter Study for Pancreatic Cancer Prevention(PREVENPANC) | not yet recruiting | — | 900 | Hospital Clinic of BarcelonaOTHER | 0 | Jan 7, 2025 | clinicaltrials |
| NCT06759090 | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer | not yet recruiting | Phase 2 | 43 | Zhejiang UniversityOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT06753318 | Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions | not yet recruiting | N/A | 716 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06310993 | Exercise to Boost Immunity in Advanced Cancer(BICEP) | not yet recruiting | N/A | 30 | Sheffield Teaching Hospitals NHS Foundation TrustOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06703905 | Conventional Partial Pancreatoduodenectomy Versus an Extended Pancreatoduodenectomy for Pancreatic Head Cancers | not yet recruiting | N/A | 270 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Nov 25, 2024 | clinicaltrials |
| NCT06700603 | Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer | not yet recruiting | Phase 2 | 48 | Rui-hua Xu, MD, PhDOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT06688240 | A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)(SEOPAC) | not yet recruiting | — | 120 | Servier (Tianjin) Pharmaceutical Co. LTD.INDUSTRY | 0 | Nov 14, 2024 | clinicaltrials |
| NCT06677762 | Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer | not yet recruiting | — | 55 | Ruijin HospitalOTHER | 0 | Nov 7, 2024 | clinicaltrials |
| NCT06669078 | NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer(NALIRIFOX) | not yet recruiting | Phase 2 | 120 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 1, 2024 | clinicaltrials |
| NCT06662669 | YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer | not yet recruiting | Phase 1 / Phase 2 | 120 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Oct 29, 2024 | clinicaltrials |
| NCT06645301 | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies | not yet recruiting | Early Phase 1 | 15 | BioSyngen Pte LtdINDUSTRY | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06619886 | TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | not yet recruiting | Early Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06621095 | Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001) | not yet recruiting | Phase 2 | 104 | RenJi HospitalOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06614751 | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway | not yet recruiting | Phase 1 | 112 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06571461 | Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer | not yet recruiting | Phase 3 | 408 | CSPC Ouyi Pharmaceutical Co., Ltd.INDUSTRY | 0 | Aug 27, 2024 | clinicaltrials |
| NCT06276803 | The LINFU® U.S. Registry for the in the General Population Without Risk Factors | not yet recruiting | — | 500 | Adenocyte, LLCINDUSTRY | 0 | Jul 31, 2024 | clinicaltrials |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 80 | RenJi HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06528223 | Research of the Application of Artificial Intelligence Model "PANDA" | not yet recruiting | N/A | 200,000 | Zhejiang UniversityOTHER | 1 | Jul 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2025source: clinicaltrials